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Running title: P2 receptors in porcine pancreatic arteries  
 Receptors for purines and pyrimidines are expressed throughout the cardiovascular system. 
This study investigated their functional expression in porcine isolated pancreatic arteries. 
Pancreatic arteries (endothelium intact or denuded) were prepared for isometric tension 
recording and preconstricted with U46619, a thromboxane A2 mimetic; ADP, UTP and 
MRS2768, a selective P2Y2 agonist, were applied cumulatively, while ATP and -meATP 
response curves were generated from single concentrations per tissue segment. 
Antagonists/enzyme inhibitors were applied prior to U46619 addition. ATP, -meATP, UTP 
and MRS2768 induced vasoconstriction, with a potency order of: ,-meATP > MRS2768 > 
ATP ≥ UTP. Contractions to ATP and ,-meATP were blocked by NF449, a selective P2X1 
receptor antagonist. The contraction induced by ATP, but not UTP, was followed by 
vasorelaxation. Endothelium removal and DUP 697, a cyclooxygenase-2 inhibitor, had no 
significant effect on contraction to ATP, but attenuated that to UTP, indicating actions at 
distinct receptors. MRS2578, a selective P2Y6 receptor antagonist, had no effect on 
contractions to UTP. ADP induced endothelium-dependent vasorelaxation which was inhibited 
by MRS2179, a selective P2Y1 receptor antagonist, or SCH58261, a selective adenosine A2A 
receptor antagonist. The contractions to ATP and -meATP were attributed to actions at 
P2X1 receptors on the vascular smooth muscle, whereas it was shown for the first time that 
UTP induced an endothelium-dependent vasoconstriction which may involve P2Y2 and/or 
P2Y4 receptors. The relaxation induced by ADP is mediated by P2Y1 and A2A adenosine 
receptors. Porcine pancreatic arteries appear to lack vasorelaxant P2Y2 and P2Y4 receptors. 
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diphosphate; ATP, Adenosine-5'-triphosphate; EDCFs, endothelium-derived contractile 
factors; ENTPDase, ecto-nucleotidase 5´-triphosphate diphosphohydrolase; PPADS, pyridoxal 
phosphate-6-azo(benzene-2,4-disulfonic acid); UTP, uridine-5'-triphosphate; VSMCs, 
vascular smooth muscle cells; XAC, xanthine amine congener. 
 
Introduction 
 
The activities of both exocrine and endocrine cells of the pancreas are regulated by autonomic 
nerves (parasympathetic and sympathetic), as well as by hormones, and autocrine and paracrine 
mediators. Although the exact mechanisms remain to be established, it is generally agreed that 
an increase in endocrine cell activity during hormone secretion corresponds with an increase 
in blood flow, to meet metabolic demand. The role of exogenous purine and pyrimidine 
nucleotides in controlling the functions of endocrine and exocrine components of the pancreas 
are well described [1, 2], but little is known about their effects on pancreatic arterial 
vasocontractility.  
There are two main families of P2 purine and pyrimidine receptors, ionotropic P2X and G 
protein-coupled P2Y receptors. Molecular cloning has identified seven mammalian P2X-
receptor subunits: P2X1, P2X2, P2X3, P2X4, P2X5, P2X6 and P2X7 [3], while eight 
mammalian P2Y receptors have been identified: P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13 
and P2Y14 [4]. P2X receptors are activated by ATP and its stable, and consequently more 
potent, analogue -meATP [5, 6]. P2Y receptors can be divided on the basis of their 
endogenous agonists into adenine nucleotide-preferring (P2Y1, P2Y11, P2Y12 and P2Y13 
receptors) and uracil nucleotide or UDP-sugar-preferring (P2Y2, P2Y4, P2Y6 and P2Y14 
receptors) [7]. Among the adenine nucleotide group, the human P2Y11 receptor is selectively 
 activated by ATP and fails to respond to ADP [8], although the dog orthologue responds to 
both ADP and ATP [9]. P2Y1, P2Y12, and P2Y13 receptors are activated by ADP, and with 
lower potency by ATP [10-13]. Among the uracil nucleotide or UDP-sugar receptors, P2Y2 is 
equally activated by ATP and UTP, while P2Y4 receptor is highly selective for UTP over ATP 
[14]. The P2Y6 receptor is activated by UDP and UTP, while the P2Y14 receptor is activated 
by UDP and UDP-sugars [6, 15].  
Within the pancreatic vasculature, P2X1, P2X2, P2Y1 and P2Y2 receptors were detected by 
immunohistochemistry [16]. More than two decades ago it was shown that P2X receptors 
mediate pancreatic vasoconstriction and P2Y receptors mediate vasodilatation in response to 
ATP [17], and subsequent studies showed an additional  involvement of contractile receptors 
sensitive to UTP (named P2U receptors) [18]. Purine receptor sub-classification has advanced 
significantly since that time. A re-evaluation of purine receptors in the pancreatic vasculature 
is clearly warranted. In the current study, we describe the pharmacological characterisation of 
P2Y1 and A2A receptor-mediated relaxatory responses, in addition to P2X1, P2Y2 and P2Y4 
receptor-mediated contractile responses of porcine isolated pancreatic artery preparations. 
P2Y2 and/or P2Y4 receptors appear to be expressed mainly in endothelial cells, while P2X1 
and A2A receptors appear to be expressed in smooth muscle cells of the pancreatic arteries. A 
preliminary account of some of these data has previously been presented to the British 
Pharmacological Society [19]. 
 
Materials and methods 
Tissue Preparation 
Pancreases from pigs (either sex, age less than 6 mo, wt ~50 kg) were obtained on ice from a 
local abattoir (G Wood & Sons Ltd, Mansfield). A crude dissection was conducted to isolate 
 the porcine pancreatic arteries (greater pancreatic artery) which were located in the body of the 
pancreas. The vessels were dissected out and placed in Krebs’-Henseleit buffer containing 2% 
(w/v) Ficoll (hydrophilic polysaccharide, type 70) and were refrigerated overnight at 4ºC. The 
next day, a fine dissection was performed on arteries, and the artery segments were cut into 
rings of about 0.5 cm in length and suspended in Krebs’-Henseleit buffer (gassed, 95% O2, 5% 
CO2).  
The endothelium of some arteries was removed by gently rubbing the innermost surface of the 
artery with forceps on a paper tissue before attaching it to the setup [20]. Successful removal 
of endothelium was tested using substance P (10 nM). Endothelium-denuded arteries relaxed 
in response to substance P to less than 10% of the U46619-induced contraction, while in 
endothelium-intact arteries the relaxation to substance P was 36% ± 8 (n=7, data not shown). 
 
Responses in the porcine isolated pancreatic artery 
 
Arterial rings were mounted onto wires in tissue baths containing warm (37°C), oxygenated 
Krebs’-Henseleit solution and were connected via isometric force transducers 
(mechanotransducer MLT 050/D, ADInstruments, Sydney, Australia) to a PC running the 
computer program, LabChart (ADInstruments, Sydney, Australia). Rings were put under 
tension (15 g) and allowed to equilibrate for 60 min before assessing viability with two 
challenges of 75 mM potassium chloride (KCl). The tissues were then allowed to equilibrate 
for 60 min, after which U46619 (10 - 100 nM), a thromboxane A2 mimetic, was used to contract 
the tissues to between 40-80% of the second KCl response. This ensured that if there was a 
vasodilator component to the response, this could be detected. Once an appropriate level of 
U46619 response had been achieved, ATP, -meATP, UTP, ADP or MRS2768 were added. 
Antagonists or enzyme inhibitors were applied 10 min prior to the addition of U46619, 
 allowing them to be incubated with the tissues for a minimal contact time of 30 min prior to 
the application of agonists. Some arteries were incubated with 0.1 % (v/v) DMSO (vehicle 
control). 
 
Reagents and Drugs 
Krebs’-Henseleit buffer was composed of the following (mM): NaCl 118, KCl 4.8, CaCl2.H2O 
1.3, NaHCO3 25.0, KH2PO4 1.2, MgSO4.7H2O 1.2 and glucose 11.1. Suramin, UTP, ATP, -
meATP, ADP, U46619, xanthine amine congener (XAC), and SCH58261 (7-(2-phenylethyl)-
5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine) were purchased from 
Sigma (Poole, Dorset, UK), while DUP 697 (5-Bromo-2-(4-fluorophenyl)-3-[4-
(me-thylsulfonyl)phenyl]-thiophene), pyridoxal phosphate-6-azo(benzene-2,4-disulfonic acid) 
(PPADS), MRS2578 (N,N″-1,4-butanediyl bis(N′-[3-isothiocynatophenyl)] thiourea)), 
MRS2179 (2'-Deoxy-N6-methyladenosine 3',5'-bisphosphate tetrasodium salt), MRS2768 
(Uridine-5'-tetraphosphate δ-phenyl ester tetrasodium salt) and substance P were purchased 
from Tocris Biosciences Ltd. (Bristol, UK). NF449 (4,4',4'',4'''-[Carbonylbis(imino-5,1,3-be-
nzenetriyl-bis(carbonylimino))]tetrakis-1,3-benzenedisulfonic acid) was purchased from 
Calbiochem-Merck4Biosciences. U46619 was dissolved in ethanol at 10 mM stock 
concentration. PPADS, suramin, -meATP, ATP, ADP, UTP, NF449, MRS2179, MRS2768 
and substance P were dissolved in distilled water. DUP 697, XAC, MRS2578 and SCH58261 
were dissolved in DMSO at 10 mM stock concentration.  
 
 
 
 Data Analysis 
The contractions to ATP, -meATP and UTP were measured from the stabilised U46619-
induced response and were expressed in g, while the relaxations to ATP and ADP were 
expressed as a percentage of the U46619-induced contraction. Data were expressed as log 
concentration-response plots. Values for all figures refer to mean ± S.E.M with 95% 
confidence. Results were compared by one-way ANOVA or two-way ANOVA with 
Bonferroni’s post hoc test or unpaired Student’s t-test (Prism, GraphPad, San Diego, CA, 
USA). Differences were considered to be significant when the P value was < 0.05. N expresses 
the number of animals. 
 
Results 
Effect of purine and pyrimidine nucleotides on vascular tone in porcine isolated 
pancreatic arteries 
To investigate the effect of purine and pyrimidine nucleotide agonists on porcine pancreatic 
arteries, -meATP (10 nM to 100 µM), ATP (1 µM to 10 mM), UTP (10 µM to 1 mM), ADP 
(1 µM to 1 mM) and MRS2768 (100 nM to 30 µM) were applied after preconstriction with 
U46619. The responses to ATP and -meATP were found to desensitise rapidly. Therefore, 
they were applied at single concentrations (one concentration per tissue segment). The 
responses to UTP, ADP and MRS2768 did not desensitise rapidly, thus cumulative 
concentration-response curves were generated. ATP, -meATP, UTP and MRS2768 induced 
concentration-dependent contraction with a potency order of -meATP > MRS2768 > ATP 
≥ UTP (P < 0.001, two-way ANOVA; Fig 1A). The response to ATP was biphasic, since its 
contraction was followed by a relaxation (Fig 1B) which was equipotent to the concentration-
 dependent relaxation produced by ADP (Fig 1A). The efficacies of ATP and -meATP in 
inducing contraction were similar, and were greater than that of UTP or MRS2768. The 
relaxation to ADP and ATP at the highest concentration of the agonists used (1 mM) was 
similar at 4.5 ± 0.5g (n=10) and 5.5 ± 0.2g (n=7) respectively; there was no significant 
difference between these responses (Fig 1A). UTP, MRS2768 and -meATP did not elicit 
vasorelaxation. 
 
Characterisation of responses to ATP and -meATP in U46619-preconstricted porcine 
isolated pancreatic arteries: 
 Effect of suramin, PPADS and -meATP 
Responses to ATP and -meATP were characterised using the non-selective P2 receptor 
antagonists suramin (100 µM) and PPADS (10 µM). Both suramin and PPADS significantly 
attenuated the contractions-evoked by ATP (1 mM) and -meATP (1 µM), (Fig 2A, 2B). 
These concentrations of ATP and -meATP were chosen since they produced robust and 
submaximal responses, and for -meATP, the concentration was close to the EC50 value 
(mean EC50 value was 1.6 µM (95% confidence interval (CI): 1.05 to 2.53 µM; n=8; Fig 1A). 
The relaxation to ATP was not affected by suramin or PPADS (Fig 2C). Since -meATP 
induces desensitisation of P2X receptors more readily than ATP because it is broken down 
more slowly than ATP [5], the responses to ATP and -meATP were studied in the presence 
of -meATP, in which -meATP (1 µM)  was added 10 min prior the addition of U46619. 
As seen in Fig 2A and 2B, the contractions to ATP and -meATP were reduced in the 
presence of the desensitising agent, while the relaxation to ATP was not affected (Fig 2C). 
 
 
  Effect of NF449, a selective P2X1 receptor antagonist  
Contractile responses to -meATP suggests expression of P2X1 receptors in porcine 
pancreatic arteries (Fig 2B). In turn, the involvement of P2X1 receptors in contraction to ATP 
seems likely because contraction was significantly blocked by -meATP (Fig 2A). The 
responses to ATP and -meATP were studied further in the presence of NF449 (10 µM), a 
P2X1 receptor selective antagonist. The contractions to ATP and -meATP were inhibited in 
the presence of NF449 (Fig 3). 
 
 Effect of endothelium removal 
The response to ATP was tested after the endothelium had been removed. The contraction and 
the relaxation induced by ATP (Fig 4) were statistically not significantly different in the 
absence or presence of the endothelium. Similarly, removal of the endothelium had no effects 
on the contractions to KCl, U46619 or -meATP; for example, the contraction to 75 mM KCl 
was 9.5 ± 0.5g in endothelium-intact arteries, while it was 9 ± 0.5g in endothelium-denuded 
arteries (n=7-9). The contraction to 10 - 100 nM U46619 was 5.5 ± 0.5g in endothelium-intact 
arteries, while it was 5.8 ± 0.6g in endothelium-denuded arteries (n=12-14). The contraction to 
1 µM -meATP was 3.2 ± 0.6g in endothelium-intact arteries, while it was 3 ± 0.6g in 
endothelium-denuded arteries (n=6); there was no significant difference between these 
responses. 
 
 
 
 
  Effect of XAC, an adenosine receptor antagonist 
The relaxation to ATP was investigated in the presence of a non-selective adenosine receptor 
antagonist; XAC (10 µM) had no effect on the contraction-evoked by ATP (Fig 5A), while it 
reduced significantly the relaxation to ATP (Fig 5B). 
 
Characterisation of response to UTP in U46619-preconstricted porcine isolated 
pancreatic arteries:  
 Effect of suramin, PPADS, -meATP and MRS2578, a selective P2Y6 
receptor antagonist 
The contraction to UTP was examined in the presence of suramin (100 µM), PPADS (10 µM), 
-meATP (1 µM) and MRS2578 (10 µM). Suramin and PPADS significantly reduced the 
contraction to UTP (Fig 6), while the UTP responses were not affected after P2X receptor 
desensitisation in the presence of -meATP (1 µM) or in the presence of a selective P2Y6 
receptor antagonist (MRS2578); for example, the contraction to 1 mM UTP was 1.8 ± 0.2g in 
the absence of MRS2578 (n=7), while it was 2.1 ± 0.2g in the presence of MRS2578 (n=6); 
there was no significant difference between these responses. 
 
 Effect of endothelium removal 
The effects of UTP were studied after the endothelium had been removed. The contraction 
induced by UTP was significantly attenuated in the endothelium-denuded arteries (Fig 7).  
 
 
  Effect of DUP 697, a cyclooxygenase-2 inhibitor 
Because the contraction to UTP was largely endothelium-dependent, the contraction was 
studied in the presence of DUP 697, a cyclooxygenase-2 (COX-2) inhibitor, since COX-2 
facilitates the release of agents which are responsible for endothelium-dependent contraction. 
DUP 697 (3 µM) diminished the response to UTP (Fig 8) to a similar extent as removal of the 
endothelium (Fig 7), while DUP 697 did not alter the contraction to U46619 (the 
preconstriction agent) or the contraction to ATP (data not shown). 
 
Characterisation of response to ADP in U46619-preconstricted porcine isolated 
pancreatic arteries:  
 Effect of MRS2179, a P2Y1 receptor selective antagonist, and of endothelium 
removal 
The relaxation to ADP in pancreatic arteries was studied in the presence of MRS2179 (10 µM), 
and after the endothelium had been removed. The relaxation to ADP was reduced slightly but 
significantly in the presence of MRS2179 (Fig 9A) and in the endothelium-denuded arteries 
(Fig 9B), which indicates the involvement of P2Y1 receptors and the endothelium in ADP-
mediated relaxation of porcine pancreatic arteries. 
 Effect of XAC, an adenosine receptor antagonist, and SCH58261, a selective 
adenosine A2A receptor antagonist  
 
The relaxation to ADP was investigated in the presence of XAC (10 µM). The relaxation to 
ADP was largely reduced in the presence of this inhibitor which indicates the involvement of 
adenosine receptors (Fig 10). To find out about the adenosine subtype involved in the relaxation 
to ADP, the response to ADP was investigated in the presence of SCH58261, a selective 
 adenosine A2A receptor antagonist. This antagonist significantly inhibited the relaxation to 
ADP, to a similar extent as seen with XAC (Fig 10). This showed that the relaxation to ADP 
involved A2A adenosine receptors. 
 
Discussion 
The current report has provided evidence for the functional expression of contractile P2X1, 
P2Y2 and P2Y4 receptors, and vasorelaxant P2Y1 and A2A adenosine receptors in porcine 
pancreatic arteries. These receptors are sensitive to the extracellular nucleotides ATP (P2X1), 
UTP (P2Y2 and P2Y4) and ADP (P2Y1 and A2A). The contraction to ATP was endothelium-
independent, while UTP induced an endothelium-dependent contraction which may involve 
P2Y2 and/or P2Y4 receptors. The relaxation to ADP involved the endothelium and P2Y1 
receptors and A2A adenosine receptors. 
 
A vasoconstrictor response elicited by ATP has been reported in a number of different arteries 
[21-23]. ATP may also induce vasorelaxation depending on the experimental conditions (level 
of pre-tone) and relative expression of relevant vasocontractile and vasorelaxant receptors [24, 
25]. In porcine pancreatic arteries, ATP induced a biphasic response consisting of a contraction 
followed by a relaxation (Fig 1B). Since the contraction to ATP was rapidly desensitising, non-
cumulative concentration response curves were investigated. The contractions to ATP and -
meATP were reduced in the presence of suramin, PPADS, -meATP (a desensitiser of P2X1 
receptors) and NF449 (a P2X1 selective antagonist) (Fig 2A, 2B, 3A, 3B), which indicates that 
a large part of the contraction to ATP could be attributed to the activation of P2X1 receptors. 
Moreover, the contractile effect of -meATP is consistent with expression of P2X1 receptors 
in porcine pancreatic arteries. -meATP was more potent than ATP in eliciting 
vasoconstriction most likely due to its greater stability [5]. Since the contraction to ATP was 
 not changed after the endothelium had been removed (Fig 4A), the expression of P2X1 
receptors was shown to be on the vascular smooth muscle cells (VSMCs). This is consistent 
with the abundant expression of P2X1 receptors on VSMCs of most tissues [7]. 
 
ATP-induced vasorelaxation was not affected after the endothelium had been removed, or in 
the presence of suramin or PPADS, which suggests that the relaxation to ATP was not due to 
its action at P2Y receptors. However, the relaxation to ATP was significantly inhibited in the 
presence of XAC, which suggested an involvement of adenosine receptors expressed on 
VSMCs of the pancreatic arteries; it is likely that this is due to the activity of adenosine derived 
from ATP metabolism by ecto-nucleotidase 5´-triphosphate diphosphohydrolase (ENTPDases) 
enzymes followed by the activity of CD37 and ecto-5´nucleotidase enzymes [26]. Similarly, in 
rat coronary arteries, the relaxation to ATP involved P1 receptors, although there was an 
additional involvement of P2Y receptors [24]. In the current study, further investigation of the 
adenosine receptor subtypes involved in the relaxation to ATP is required. We and others have 
shown previously a slow relaxation in response to -meATP in rat mesenteric arteries, 
subsequent to contraction [27-29], but we did not observe this in the present study in the porcine 
pancreatic arteries. 
 
The vasoconstriction to UTP did not desensitise quickly, therefore, cumulative concentration 
response curves were used to study the effect of UTP on pancreatic arteries. This contraction 
was significantly inhibited by suramin and PPADS (Fig 6), and there was a reduction of the 
response after the removal of the endothelium (Fig 7). That would indicate for the first time an 
endothelium-dependent vasoconstriction-evoked by UTP. UTP is known to be active at P2Y2, 
P2Y4 and P2Y6 receptors [30]. The expression of these receptors in the endothelium and the 
smooth muscle of vessels has been reported [31]. Since MRS2578 was not able to alter the 
 contraction to UTP, this indicates that UTP had no action at P2Y6 receptors. There are currently 
no commercially available selective antagonists for either P2Y2 or P2Y4 receptors. However, 
we believe that UTP acted at P2Y4 receptors since the contraction to UTP was significantly 
inhibited by both endothelium removal and in the presence of DUP 697, but responses to ATP 
were unaffected. UTP induced-contraction may also be mediated by P2Y2 receptors, since 
MRS2768 which is a selective agonist at P2Y2 receptors and displays no affinity for P2Y4 or 
P2Y6 receptors was able to evoke a contraction in pancreatic arteries [32]  (Fig 1A).  
UTP-induced vasoconstriction has been documented in a number of arteries including rat 
pulmonary arteries in which the contraction was attributed to P2Y2 receptors, and in rabbit 
basilar arteries in which the contraction to UTP was due to action of P2Y4 receptors [33, 34]. 
UTP produced an endothelium-dependent relaxation in rabbit pulmonary arteries and in rat 
mesenteric arterial bed, but the receptor subtypes were undefined [22, 35]. In bovine middle 
cerebral arterial strips, UTP had a dual response, it induced a contraction in endothelium-
denuded arteries but a relaxation in endothelium-intact arteries [36]. The absence of 
endothelium-dependent or -independent relaxation to UTP and some other nucleotides in rat 
renal arteries was reported [37], which is consistent with the current study since there was no 
evidence of a UTP-mediated relaxation in porcine pancreatic arteries. Hence, porcine 
pancreatic arteries appear not to express relaxant P2Y2 and/ or P2Y4 receptors. 
 
To investigate the mechanism underlying the contraction mediated by UTP in pancreatic 
arteries, the response to UTP was examined in the presence of DUP 697. As seen in Fig 8, the 
endothelium-dependent contraction was attenuated in the presence of the selective COX-2 
inhibitor. Endothelial cells can release endothelium-derived contractile factors (EDCFs), which 
may include thromboxane A2, prostaglandin F2α, leukotrienes and endothelin-1. Thromboxane 
A2 and prostaglandin F2α are released from the endothelium due to the activity of COX-2 [38, 
 39]. The reduction of the contraction to UTP in the presence of DUP 697 indicated the 
involvement of thromboxane A2 and prostaglandins in the contraction to UTP. These agents, 
after being released from the endothelium, may act on their receptors on VSMCs to cause 
contraction [39]. The different effect of DUP 697 on responses to UTP and ATP further 
suggests that they are acting on different receptors. 
 
The relaxation to ADP did not desensitise rapidly, therefore, cumulative concentration response 
curves were used to study the effect of ADP on pancreatic arteries. The relaxation was 
significantly attenuated by MRS2179, a selective P2Y1 receptor antagonist (Fig 9A). In 
addition, the relaxation to ADP was reduced after the endothelium had been removed, by a 
similar extent as observed in presence of the MRS2179 (Fig 9B). This may suggest that P2Y1 
receptors are expressed on the endothelium. Indeed, a number of reports show that P2Y1 
receptors are expressed on the endothelium and are responsible for the relaxation of arteries, 
including rat thoracic aortic and porcine mesenteric arteries [40, 41]. The relaxation to ADP in 
our study was largely reduced in the presence of XAC and SCH58261 (adenosine receptor 
antagonists). Adenosine receptors may be expressed on the endothelium or the vascular smooth 
muscle [42]. Since XAC and SCH58261 produced a greater reduction in the relaxation to ADP 
than the inhibition induced by removal of the endothelium (Fig 10), this suggests that relaxation 
to ADP involves A2A adenosine receptors expressed, at least in part, on VSMCs. The 
mechanism by which ADP would produce adenosine to act at the adenosine receptors is still to 
be elucidated. The simplest explanation is that it is broken down by ENTPDases and by 
CD37enzymes to adenosine [26]. Alternatively, as suggested in porcine coronary arteries, ADP 
mediates a relaxation via a mechanism that involves ADP-evoked adenosine release and the 
subsequent activation of A2A receptors [20]. In contrast to the porcine pancreatic vessels, ADP 
in rat pancreatic arteries induced a contraction at a high concentration (1 mM); this contraction 
 was similar to that produced by ATP and was much lower than the contraction induced by -
meATP [43]. Further investigation is required to determine the involvement of endothelium-
derived relaxing factors or endothelium-derived hyperpolarising factors released from the 
endothelium in the ADP-induced relaxation. 
 
Reduction in pancreatic blood flow has been observed in acute and chronic pancreatitis and 
some other pancreatic diseases [44, 45], implicating pancreatic tissue perfusion as an important 
factor in pathogenesis of pancreatic diseases and symptoms. There is increasing evidence for 
the role of purinergic signalling in the pathophysiology of the pancreas [2]. Hence, drugs 
designed to target specific components of purinergic system may be of relevance to the 
management of pancreatitis, cystic fibrosis, pancreatic cancer and diabetes.  
 
In summary, the functional expression of P2X1 and A2A adenosine receptors on VSMCs, and 
P2Y2 and/or P2Y4 receptors on the endothelium of porcine pancreatic arteries was indicated in 
the current study. Activation of P2X1 receptors by ATP or -meATP induced a 
vasoconstriction, and UTP acts at P2Y2 and/or P2Y4 receptors to induce a contraction. ADP 
and ATP activate A2A adenosine receptors to induce relaxation, together with an action of ADP 
on P2Y1 receptors. Pancreatic arteries appear to lack vasorelaxant P2Y2 and/or P2Y4 receptors. 
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 Figure Legends 
 
Fig 1. (A) Concentration-dependent contraction of ATP, -meATP, UTP and MRS2768, a 
selective P2Y2 agonist, and relaxation of ADP and ATP in U46619-preconstricted porcine 
pancreatic arteries (n=7-12). (B) Typical trace showing the biphasic response to ATP 
(contraction followed by relaxation). Data are presented as mean ± SEM. 
 
Fig 2. Effect of suramin (100 µM), PPADS (10 µM) and desensitisation by -meATP (1 µM) 
on contractions to (A) ATP (1 mM), (B) -meATP (1 µM), and (C) on the relaxation to ATP 
in U46619-preconstricted porcine pancreatic arteries. PPADS, suramin and -meATP 
reduced the contractions of (A) ATP and (B) -meATP (**P < 0.01, ***P < 0.001, one-way 
ANOVA with Bonferroni’s post hoc test, responses of ATP or -meATP vs their responses 
in the presence of PPADS, suramin or -meATP, n=6-9). (C) The relaxation to ATP was not 
significantly different in the absence or in the presence of PPADS, suramin or -meATP 
(n=7). Data are presented as mean ± SEM. 
 
Fig 3. Effect of NF449 (10 µM), a selective P2X1 receptor antagonist, on contractions to (A) 
ATP (1 mM), (B) -meATP (1 µM), in U46619-preconstricted porcine pancreatic arteries. 
NF449 reduced the effects of (A) ATP and (B) -meATP (***P < 0.001, unpaired Student’s 
t-test, n=10-13). Data are presented as mean ± SEM. 
 
Fig 4. Effect of removal of the endothelium on (A) contraction, (B) relaxation to ATP (1 mM) 
in U46619-preconstricted porcine pancreatic arteries. The effect of the removal of endothelium 
 on the contraction or relaxation of ATP was not significantly different (n=9-11). Data are 
presented as mean ± SEM. 
 
Fig 5. Effect of XAC (10 µM) on (A) contraction, (B) relaxation to ATP (1 mM) in U46619-
preconstricted porcine pancreatic arteries. (A) XAC had no effect on the contraction to ATP 
(n=8-10), (B) XAC reduced the relaxation to ATP (***P < 0.001, unpaired Student’s t-test, 
n=8-10). Data are presented as mean ± SEM.  
 
Fig 6. Effect of suramin (100 µM) and PPADS (10 µM) on contraction to UTP in U46619-
preconstricted porcine pancreatic arteries. With suramin and PPADS, effect of UTP 
concentration (F=16.77, 12.38 respectively, ***P < 0.001); suramin and PPADS reduced the 
contraction-evoked by UTP (F=14.47, 12.48 respectively, ***P < 0.001, two-way ANOVA; 
n=9-12). Data are presented as mean ± SEM. 
 
Fig 7. Effect of removal of the endothelium on contraction to UTP in U46619-preconstricted 
porcine pancreatic arteries. Effect of UTP concentration (F= 11.91, ***P < 0.001); removal of 
endothelium reduced the contraction-evoked by UTP (F=43, ***P < 0.001, two-way ANOVA; 
n=10-12). Data are presented as mean ± SEM. 
 
Fig 8. Effect of DUP 679 (3 µM), a cyclooxygenase-2 inhibitor, on contraction to UTP in 
U46619-preconstricted porcine pancreatic arteries. Effect of UTP concentration (F= 8.48, ***P 
< 0.001); DUP 679 reduced the contraction-evoked by UTP (F=50.8, ***P  <  0.001, two-way 
ANOVA; n=8-12). Data are presented as mean ± SEM. 
 
 
 Fig 9. Effect of (A) MRS2179 (10 µM), (B) the removal of the endothelium on relaxation to 
ADP in U46619-preconstricted porcine pancreatic arteries. With MRS2179 and in 
endothelium-denuded arteries, effect of ADP concentration (F=21.42, 16.77 respectively, ***P 
< 0.001); MRS2179 and removal of endothelium reduced the contraction-evoked by ADP 
(F=21.42, F=32.04 respectively, ***P < 0.001, two-way ANOVA; n=10-12). Data are 
presented as mean ± SEM. 
 
Fig 10. Effect of XAC (10 µM), a non-selective adenosine receptor antagonist, and SCH58261 
(1 µM), a selective adenosine A2A receptor antagonist, on relaxation to ADP in U46619-
preconstricted porcine pancreatic arteries. With XAC and SCH58261, effect of ADP 
concentrations (F=7.14, 6.08 respectively, ***P < 0.001); XAC and SCH58261 reduced the 
relaxation-evoked by ADP (F=71.19, 58.16 respectively, ***P < 0.001, two-way ANOVA; 
n=9-14). Data are presented as mean ± SEM.        
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